Asciminib is a targeted anticancer drug used in the treatment of Chronic Myeloid Leukemia, particularly in patients who are resistant or intolerant to prior therapies. It works through a unique mechanism by specifically inhibiting the BCR-ABL1 protein at a different site than traditional tyrosine kinase inhibitors, thereby improving treatment outcomes with potentially fewer side effects. The development of asciminib represents a significant advancement in targeted cancer therapy, as it belongs to a newer class known as STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitors. The history of asciminib traces back to research efforts aimed at overcoming resistance seen with earlier treatments, leading to its development by Novartis. After successful clinical trials demonstrating its efficacy and safety, it was approved in 2021 by the U.S. Food and Drug Administration and is marketed under the brand name Scemblix, marking an important milestone in leukemia treatment.
